Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

We have observed 7 EP applications Alastair George Sayce has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 15, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12702009

NOVEL ANTIGEN BINDING PROTEINS

IPC classification:
C07K 16/22
Applicant:
Glaxo Group Limited
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP12735498

THERAPEUTIC COMBINATIONS OF ANTI -CD20 AND ANTI - GM - CSF ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/395, C07K 16/24, C07K 16/28
Applicant:
MorphoSys AG
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11742704

NOVEL USES

IPC classification:
C12P 21/06
Applicant:
GlaxoSmithKline LLC
Agent:
Alastair George Sayce, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13784908

NOVEL ANTIBODIES

IPC classification:
A61K 39/395
Applicant:
GlaxoSmithKline LLC
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13732986

OPTIMUM DOSE REGIME OF AN ANTI-NOGO-A ANTIBODY IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

IPC classification:
C07K 16/22
Applicant:
Glaxo Group Limited
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP15155712

Antibody formulations

IPC classification:
A61K 9/00, A61K 39/395, C07K 16/00, C07K 16/28
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Agent:
Alastair George Sayce, GlaxoSmithKline
Status:
The patent has been granted
EP12734212

NOVEL USES

IPC classification:
A61K 39/395
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Agent:
Alastair George Sayce, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS

Please Sign in to use this feature